Published in Br Heart J on May 01, 1987
Mortality in heart failure: clinical variables of prognostic value. Br Heart J (1987) 1.67
Decreased cardiac parasympathetic activity in chronic heart failure and its relation to left ventricular function. Br Heart J (1992) 1.21
Cardiovascular effects of training for a marathon run in unfit middle aged men. Br Med J (Clin Res Ed) (1987) 1.06
Side effects with amiodarone therapy. Postgrad Med J (1994) 0.84
Amiodarone in long term prophylaxis. Drugs (1991) 0.79
Impact of concurrent amiodarone treatment on the tolerability and efficacy of carvedilol in patients with chronic heart failure. Heart (1999) 0.79
The effect of long-term amiodarone administration on myocardial fibrosis and evolution of left ventricular remodeling in a porcine model of ischemic cardiomyopathy. Springerplus (2016) 0.78
Current treatment of dilated cardiomyopathy. Tex Heart Inst J (1991) 0.75
The natural history of congestive heart failure: the Framingham study. N Engl J Med (1971) 13.94
Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med (1984) 6.74
The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol (1970) 5.24
Side effects of long-term amiodarone therapy. Circulation (1983) 3.03
Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J (1975) 2.71
Amiodarone pharmacokinetics. Am Heart J (1983) 2.42
Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol (1983) 2.24
Circulating dopamine: its effect on the plasma concentrations of catecholamines, renin, angiotensin, aldosterone and vasopressin in the conscious dog. Clin Sci (Lond) (1981) 1.76
A comparison of double-isotope derivative and radioimmunological estimation of plasma aldosterone concentration in man. Clin Sci Mol Med (1973) 1.76
Significance of ventricular arrhythmias in idiopathic dilated cardiomyopathy. Am J Cardiol (1984) 1.62
Amiodarone increases plasma digoxin concentrations. Br Med J (Clin Res Ed) (1981) 1.61
Factors influencing the one-year mortality of dilated cardiomyopathy. Am J Cardiol (1984) 1.57
Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias. J Am Coll Cardiol (1983) 1.51
Effects of verapamil on myocardial performance in coronary disease. Circulation (1979) 1.50
The QT interval: a predictor of the plasma and myocardial concentrations of amiodarone. Br Heart J (1984) 1.49
Cardiac actions in the dog of a new antagonist of adrenergic excitation which does not produce competitive blockade of adrenoceptors. Br J Pharmacol (1970) 1.47
Long-term management of sustained, recurrent, symptomatic ventricular tachycardia with amiodarone. Circulation (1981) 1.22
Arrhythmias in ischemic and nonischemic dilated cardiomyopathy: prediction of mortality by ambulatory electrocardiography. Am J Cardiol (1985) 1.19
Ventricular arrhythmias in idiopathic dilated cardiomyopathy. Br Heart J (1984) 1.14
Effects of amiodarone on cardiac and coronary hemodynamics and on myocardial metabolism in patients with coronary artery disease. Circulation (1979) 1.14
Use of isoproterenol as an aid to electric induction of chronic recurrent ventricular tachycardia. Am J Cardiol (1979) 1.10
Amiodarone: the experience of the past decade. Br Med J (Clin Res Ed) (1983) 1.04
Prospective evaluation of amiodarone pulmonary toxicity. Chest (1984) 0.98
Ventricular arrhythmias in severe heart failure: incidence, significance, and effectiveness of antiarrhythmic therapy. Am Heart J (1985) 0.96
Hemodynamic effects of intravenous flecainide relative to the level of ventricular function in patients with coronary artery disease. Am Heart J (1985) 0.96
Haemodynamic effects of atenolol in patients with coronary artery disease. Br Heart J (1978) 0.96
Ambulatory electrocardiographic recordings at the time of fatal cardiac arrest. Am J Cardiol (1985) 0.94
Effects of amiodarone and L8040, novel antianginal and antiarrhythmic drugs, on cardiac and coronary haemodynamics and on cardiac intracellular potentials. Clin Exp Pharmacol Physiol (1976) 0.94
Correlative studies of serum digitalis levels and the arrhythmias of digitalis intoxication. Am J Cardiol (1978) 0.92
Arrhythmias in dilated and hypertrophic cardiomyopathy. Med Clin North Am (1984) 0.91
Cardiac function in patients on chronic amiodarone therapy. Am Heart J (1985) 0.91
Determination of cardiac and plasma drug levels during long-term amiodarone therapy. Eur J Clin Invest (1983) 0.90
Massive digoxin overdose: successful treatment with intravenous amiodarone. Br Med J (Clin Res Ed) (1983) 0.90
Hemodynamic effects of intravenous amiodarone in patients with depressed left ventricular function and recurrent ventricular tachycardia. Am Heart J (1983) 0.89
Electrophysiologic effects of chronic amiodarone therapy in patients with ventricular arrhythmias. Am Heart J (1982) 0.88
Haemodynamic effects of beta-blockade in ischaemic heart failure. Lancet (1981) 0.88
Important differences between short- and long-term hemodynamic effects of amiodarone in patients with chronic ischemic heart disease at rest and during ischemia-induced left ventricular dysfunction. J Am Coll Cardiol (1985) 0.85
Haemodynamics of intravenous disopyramide. J Int Med Res (1976) 0.85
The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure. Am Heart J (1986) 0.84
Amiodarone-induced polymorphous ventricular tachycardia. Am Heart J (1983) 0.83
Effect of amiodarone on ventricular function as measured by gated radionuclide angiography. Am J Cardiol (1984) 0.82
Hemodynamic effects of intravenous administration of amiodarone in congestive heart failure from chronic Chagas' disease. Am J Cardiol (1983) 0.80
Chronic administration of amiodarone and thyroid function: a follow-up study. Am Heart J (1984) 0.80
Amiodarone. Biochemical aspects and haemodynamic effects. Drugs (1985) 0.79
Cellular electrophysiology of amiodarone in cardiac ischaemia. Br J Clin Pract Suppl (1986) 0.78
Biochemical detection of left-ventricular systolic dysfunction. Lancet (1998) 7.51
Biotransformation of trichloroethylene in soil. Appl Environ Microbiol (1985) 6.75
Insertion of synthetic copies of human globin genes into bacterial plasmids. Nucleic Acids Res (1978) 5.99
Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J (2000) 4.99
Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet (1997) 3.70
Microbial ecology of the terrestrial subsurface. Adv Appl Microbiol (1988) 3.68
Human beta-globin messenger RNA. III. Nucleotide sequences derived from complementary DNA. J Biol Chem (1977) 3.55
Trends in hospitalization for heart failure in Scotland 1980-1990. Eur Heart J (1993) 3.35
Clinical pharmacology and pharmacokinetics of clonidine. Clin Pharmacol Ther (1976) 3.13
Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation (1999) 3.06
Captopril in heart failure. A double blind controlled trial. Br Heart J (1984) 2.85
Analyzing outcome of treatment of severe head injury: a review and update on advancing the use of the Glasgow Outcome Scale. J Neurotrauma (1998) 2.81
Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int (2006) 2.80
Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br Heart J (1985) 2.74
Direct identification of sickle cell anemia by blot hybridization. Proc Natl Acad Sci U S A (1981) 2.68
GISSI-3. Lancet (1994) 2.53
Drug excretion in human breast milk: principles, pharmacokinetics and projected consequences. Clin Pharmacokinet (1980) 2.51
Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation (2000) 2.49
Unsuspected renal artery stenosis in peripheral vascular disease. BMJ (1990) 2.42
Factors influencing coronary artery bypass graft patency. Cardiovasc Surg (1994) 2.39
Enhanced basal nitric oxide production in heart failure: another failed counter-regulatory vasodilator mechanism? Lancet (1994) 2.25
Routine prophylactic vena cava filter insertion in severely injured trauma patients decreases the incidence of pulmonary embolism. J Am Coll Surg (1995) 2.24
Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther (2007) 2.17
Severe hypotension after first dose of enalapril in heart failure. Br Med J (Clin Res Ed) (1985) 2.14
Coronary heart disease. BMJ (1991) 2.09
Nucleotide sequence of the coding portion of human alpha globin messenger RNA. J Biol Chem (1980) 2.07
Geographic, demographic, and socioeconomic variations in the investigation and management of coronary heart disease in Scotland. Heart (1999) 2.04
Flosequinan: a new vasodilator for the treatment of heart failure. Br J Hosp Med (1993) 2.03
Equivalence of microbial biomass measures based on membrane lipid and cell wall components, adenosine triphosphate, and direct counts in subsurface aquifer sediments. Microb Ecol (1988) 2.02
Reliability and validity of survey data on sexual behaviour. Health Transit Rev (1994) 2.02
Clonidine withdrawal in hypertension. Changes in blood-pressure and plasma and urinary noradrenaline. Lancet (1977) 2.01
Influence of concomitant disease on patterns of hospitalization in patients with heart failure discharged from Scottish hospitals in 1995. Eur Heart J (1998) 1.94
Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med (1987) 1.94
Nucleotide sequence of 3' untranslated portion of human alpha globin mRNA. Nucleic Acids Res (1977) 1.92
Factors affecting the prognosis in acute renal failure. A survey of 251 cases. Q J Med (1973) 1.91
The evidence for beta blockers in heart failure. BMJ (1999) 1.84
Effect of captopril, an angiotensin-converting enzyme inhibitor, in patients with angina pectoris and heart failure. J Am Coll Cardiol (1991) 1.82
Life-threatening arrhythmias and intravenous cimetidine. Br Med J (1979) 1.81
NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension. Eur Respir J (2006) 1.81
Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart (2001) 1.77
The heart failure epidemic: exactly how big is it? Eur Heart J (2001) 1.73
Prognostic value of cardiovascular screening in potential renal transplant recipients: a single-center prospective observational study. Am J Transplant (2008) 1.73
Mortality in heart failure: clinical variables of prognostic value. Br Heart J (1987) 1.67
Effects of increased inspired oxygen concentrations on exercise performance in chronic heart failure. Lancet (1992) 1.65
Helicobacter pylori infection and coronary heart disease in the North Glasgow MONICA population. Eur Heart J (1997) 1.60
Natural history of secundum atrial septal defect in adults after medical or surgical treatment: a historical prospective study. Br Heart J (1994) 1.59
Effects of early captopril administration on infarct expansion, left ventricular remodeling and exercise capacity after acute myocardial infarction. Am J Cardiol (1991) 1.59
Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J (2000) 1.55
Objective assessment of treatment in severe angina. Br Med J (1979) 1.53
Randomised controlled trial of continuous positive airway pressure and standard oxygen therapy in acute pulmonary oedema; effects on plasma brain natriuretic peptide concentrations. Eur Heart J (2002) 1.52
ACE inhibitors for myocardial infarction and unstable angina. Lancet (1993) 1.51
Echocardiography overestimates left ventricular mass in hemodialysis patients relative to magnetic resonance imaging. Kidney Int (1999) 1.50
Use of biotinylated probes for detecting sickle cell anemia. Clin Chem (1985) 1.50
Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure. Br Heart J (1991) 1.50
Is aspirin safe for patients with heart failure? Br Heart J (1995) 1.49
Cost and survival analysis of metastatic cerebral tumors treated by resection and radiation. Neurosurgery (1994) 1.49
Clinical pharmacokinetics in infants and children. Clin Pharmacokinet (1976) 1.49
Endothelin B receptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction. J Am Coll Cardiol (1999) 1.47
Plasma endothelin in chronic heart failure. Circulation (1992) 1.47
Clinical pharmacology: a discipline called to action for maternal and child health. Clin Pharmacol Ther (2007) 1.46
Genetic testing for familial hypertrophic cardiomyopathy in newborn infants. BMJ (1995) 1.44
Maintenance and stability of introduced genotypes in groundwater aquifer material. Appl Environ Microbiol (1987) 1.44
Plasma alpha natriuretic peptide in cardiac impairment. Br Med J (Clin Res Ed) (1986) 1.44
Phenylbutazone-induced blood dyscrasias suspected in three dogs. Vet Rec (1980) 1.40
Unique cardioprotective potential of angiotensin converting enzyme inhibitors: a hypothesis still to be tested on humans. J Hypertens (1991) 1.39
Lack of effect of respiratory syncytial virus infection on theophylline disposition in children. J Pediatr (1992) 1.39
Non-invasive determination of cardiac output by Doppler echocardiography and electrical bioimpedance. Br Heart J (1990) 1.36
Novel exercise protocol suitable for use on a treadmill or a bicycle ergometer. Br Heart J (1990) 1.36
Risk stratification in chronic heart failure. Eur Heart J (1998) 1.33
Pharmacokinetic pitfalls in the estimation of the breast milk/plasma ratio for drugs. Annu Rev Pharmacol Toxicol (1985) 1.31
Is the prognosis of heart failure improving? J Am Coll Cardiol (2000) 1.29
Tophaceous gout of the spine mimicking epidural infection: case report and review of the literature. Neurosurgery (2001) 1.29
Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure. Am Heart J (1999) 1.28
Reduced alveolar-capillary membrane diffusing capacity in chronic heart failure. Its pathophysiological relevance and relationship to exercise performance. Circulation (1995) 1.27
Use of restriction endonucleases for mapping the allele for beta s-globin. Proc Natl Acad Sci U S A (1982) 1.26
Human globin messenger RNA: importance of cloning for structural analysis. Science (1977) 1.25
Antioxidant effects of angiotensin-converting enzyme (ACE) inhibitors: free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl- and nonsulfhydryl-containing ACE inhibitors. J Cardiovasc Pharmacol (1992) 1.24
Assessing disability after head injury: improved use of the Glasgow Outcome Scale. J Neurosurg (1998) 1.24
Ventricular arrhythmias in hypertensive left ventricular hypertrophy. Relationship to coronary artery disease, left ventricular dysfunction, and myocardial fibrosis. Am J Hypertens (1990) 1.23
Should we screen for asymptomatic left ventricular dysfunction to prevent heart failure? Eur Heart J (1998) 1.23
Comparison of the half-life of antipyrine in plasma, whole blood and saliva of man. Eur J Clin Pharmacol (1976) 1.23
What is the ideal study design for evaluation of treatment for heart failure? Insights from trials assessing the effect of ACE inhibitors on exercise capacity. Eur Heart J (1996) 1.23
Treatment of angina pectoris with nifedipine and atenolol: efficacy and effect on cardiac function. Br Heart J (1986) 1.22
Dosing implications of altered gentamicin disposition in patients with cystic fibrosis. J Pediatr (1982) 1.19
NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. Eur J Heart Fail (2004) 1.19
Neuroendocrine activation after acute myocardial infarction. Br Heart J (1988) 1.16
Kinetics of carbamazepine and its 10,11-epoxide metabolite in children. Clin Pharmacol Ther (1976) 1.15
Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J (1993) 1.14
Reye syndrome and aspirin use: the role of prodromal illness severity in the assessment of relative risk. Pediatrics (1982) 1.14
Converting enzyme inhibitors in hypertension and heart failure. Br Heart J (1983) 1.12